Ovarian cancer arising from the proximal fallopian tube in a patient with a BRCA2 mutation

Nora Badiner; Corbyn M Nchako; Lucy Ma; Melissa K Frey

doi:10.1016/j.gore.2021.100795

Ovarian cancer arising from the proximal fallopian tube in a patient with a BRCA2 mutation

Gynecol Oncol Rep. 2021 May 25:37:100795. doi: 10.1016/j.gore.2021.100795. eCollection 2021 Aug.

Authors

Nora Badiner¹, Corbyn M Nchako¹, Lucy Ma², Melissa K Frey³

Affiliations

¹ NY Presbyterian Weill Cornell Medical Center, Department of Obstetrics and Gynecology, 525 East 68 Street, Box 122, New York, NY 10065, USA.
² NY Presbyterian Weill Cornell Medical Center, Department of Pathology and Laboratory Medicine, 525 East 68th Street, Starr Pavilion, 10 Floor, New York, NY 10021, USA.
³ NY Presbyterian Weill Cornell Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, 525 East 68th Street, Suite J-130, New York, NY 10065, USA.

Abstract

Patients with BRCA mutations are at high risk of high grade serous ovarian cancer. A paradigm shift has resulted in the current understanding that many cases of ovarian cancer actually arise from the fimbriated fallopian tube. The case presented here involves fallopian tube carcinoma arising from the cornua of the uterus in a BRCA2 carrier. This case suggests that pathologic analysis of risk-reducing bilateral salpingo-oophorectomy (RRBSO) specimens via serial sectioning and extensively examining the fimbriated end (SEE-FIM) may be insufficient to diagnose all occult lesions of interest. This case also provides a new consideration in the ongoing debate over the role of concurrent hysterectomy at time of RRBSO in BRCA carriers.

Publication types

Case Reports